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Abstract
Prion diseases are rare and fatal neurodegenerative disorders that can be sporadic, inherited or acquired by infection. Based
on a national surveillance program in the Netherlands we describe here the clinical, neuropathological, genetic and
molecular characteristics of 162 patients with neuropathologically confirmed prion disease over a 12-year period (1998–
2009). Since 1998, there has been a relatively stable mortality of Creutzfeldt-Jakob disease (CJD) in the Netherlands, ranging
from 0.63 to 1.53 per million inhabitants per annum. Genetic analysis of the codon 129 methionine/valine (M/V)
polymorphism in all patients with sporadic CJD (sCJD) showed a trend for under-representation of VV cases (7.0%),
compared with sCJD cohorts in other Western countries, whereas the MV genotype was relatively over-represented (22,4%).
Combined PrPSc and histopathological typing identified all sCJD subtypes known to date, except for the VV1 subtype. In
particular, a ‘‘pure’’ phenotype was demonstrated in 60.1% of patients, whereas a mixed phenotype was detected in 39.9%
of all sCJD cases. The relative excess of MV cases was largely accounted for by a relatively high incidence of the MV 2K
subtype. Genetic analysis of the prion protein gene (PRNP) was performed in 161 patients and showed a mutation in 9 of
them (5.6%), including one FFI and four GSS cases. Iatrogenic CJD was a rare phenomenon (3.1%), mainly associated with
dura mater grafts. Three patients were diagnosed with new variant CJD (1.9%) and one with variably protease-sensitive
prionopathy (VPSPr). Post-mortem examination revealed an alternative diagnosis in 156 patients, most commonly
Alzheimer’s disease (21.2%) or vascular causes of dementia (19.9%). The mortality rates of sCJD in the Netherlands are
similar to those in other European countries, whereas iatrogenic and genetic cases are relatively rare. The unusual incidence
of the VV2 sCJD subtype compared to that reported to date in other Western countries deserves further investigation.
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Introduction
Prion diseases, also known as transmissible spongiform enceph-
alopathies (TSEs), are fatal neurodegenerative disorders that occur
in both humans and a wide variety of animals, such as cattle,
sheep, deer and elk [1]. The most common form in humans,
accounting for 85–90% of all prion diseases, is sporadic
Creutzfeldt-Jakob disease (sCJD), which has an unknown aetiology
and occurs with a worldwide annual incidence of 1–1,5 per million
[2,3]. Familial forms make up 5–15% of the total number of cases
and follow a dominant mode of inheritance. They are caused by
pathogenic mutations in PRNP, the gene encoding the prion
protein [4]. Over 30 different mutations have been described to
date, resulting in clinico-pathological entities such as genetic CJD
(gCJD), Gerstmann-Strau¨ssler-Scheinker (GSS) disease and Fatal
Familial Insomnia (FFI) [5,6]. Finally, a small proportion of cases
(1–2%) are acquired by infection. The majority of these have been
transmitted through medical procedures (e.g. in pituitary hormone
and dura mater grafts recipients), thus the designation of
iatrogenic CJD (iCJD) [7].
The central event in prion diseases is the conversion of the
normal, physiological form of the prion protein (PrPC) into a
misfolded and aggregated b-sheet rich form, commonly referred to
as PrPSc [1]. This conversion leads to the formation of several
PrPSc ‘‘types’’ that can be distinguished on the basis of
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physicochemical properties such as the size of the fragment
resistant to treatment with proteinase K (PK), possibly reflecting
distinct protein conformations, and the relative abundance of the
three differently glycosylated isoforms of the protein (i.e. glycoform
ratio). Based on the size of the core fragment (i.e. PrP27–30)
generated by PK digestion, Parchi et al. were able to identify two
major PrPSc types: type 1 with a relative molecular mass of 21 kDa
and type 2 with a relative molecular mass of 19 kDa [8]. Evidence
indicates that the formation of these two major PrPSc types is in
part influenced by the PRNP genotype, especially the codon 129
methionine/valine (M/V) polymorphism; whilst type 1 is the most
common finding in MM subjects, type 2 largely predominates in
subjects carrying VV.
One of the major characteristics of human prion diseases is the
heterogeneity of the clinical and pathological phenotype [9]. Prion
strains, originally defined by their distinct phenotypes upon
transmission to syngenic animals, which are maintained on serial
transmission, are believed to be the main cause of this phenotypic
variability [10]. In addition, the host genotype variability in PRNP,
as determined by polymorphisms and mutations, is another
recognized causal factor for phenotypic heterogeneity [11–13].
There is now general consensus that in sCJD the M/V genotype at
codon 129 of PRNP, the type of PrPSc, as well as the ratio of the
PrPSc glycoforms, are major determinants of the disease phenotype
and can serve as surrogate ‘‘strain-typing’’ markers. The
combination of the codon 129 genotype and the PrPSc type has
allowed for the distinction of six subtypes of sCJD, each with a
characteristic incidence, and distinctive clinical and histopatho-
logical features, that are classified as (i) MM1/MV1; (ii) VV2; (iii)
MV 2K; (iv) MM 2C; (v) MM 2T or sporadic FI; and (vi) VV1
[13,14]. Although much remains to be learned about the
biological basis of prion strains, recent studies have identified at
least five distinct strains in humans that correspond to most of the
sCJD subtypes listed above [9,15,16]. These data have confirmed
that PrPSc typing in humans provides a surrogate molecular
signature for certain prion strains within a particular host
genotype, particularly when combined with neuropathological
data.
Interestingly, PrPSc types 1 and 2 have also been found to co-
exist in the same brain, often resulting in mixed clinical and
neuropathological phenotypes. This phenomenon is referred to as
‘‘co-occurrence’’ and constitutes yet another variable in the factors
that govern phenotypic variability. Although earlier studies have
argued that co-occurrence of PrPSc types is mainly a function of
the extent of brain sampling and the sensitivity with which a
minority type can be detected in the presence of larger amounts of
the other protein [17–22], two recent studies have placed firm
restriction on the prevalence of cases with mixed PrPSc types and
proposed that they constitute defined subtypes of sCJD with
distinct clinico-pathological phenotypes [23,24]. Nevertheless,
debate on its extent and biological basis continues [25–27]. So
far, information of the incidence of pure and mixed sCJD subtypes
has not yet been provided comprehensively for single countries or
areas.
National Surveillance Programs were initiated in many
countries around the world to monitor the incidence of both
existing and emerging forms of prion diseases, in particular new
variant CJD (vCJD), which is causally related to bovine
spongiform encephalopathy (BSE) in cattle [28]. In doing this,
surveillance programs have in many ways served their purpose, as
judged by the recent identification of variably protease sensitive
prionopathy (VPSPr), a novel form of sporadic prion disease [29].
In the Netherlands, a National CJD Surveillance Program was
established in 1997 to undertake prospective surveillance. In this
report, we describe the epidemiological, clinical and neuropath-
ological results of our comprehensive surveillance of prion diseases
over a 12 year period, combined with genetic studies and prion
protein characteristics.
Methods
Case selection and clinical evaluations
This study was embedded within collaborative studies monitor-
ing the incidence of CJD in several European countries, using
identical methodology. In the Netherlands, the National Prion
Disease Registry, part of the Erasmus University Medical Centre
in Rotterdam, aims to ascertain all patients with definite or probable
CJD. Treating physicians, mainly neurologists, are required by law
to notify all clinically suspected patients within two days to the
reference centre. Whenever possible, all referred cases were
classified before death by a member of the National Prion Disease
Registry according to international criteria for probable or possible
CJD or other disease, as described previously [2,30]. For patients
reported after death, classification was based on evaluation of
symptoms and signs that could be retrieved from the hospital
records.
Post mortem examinations, if permission was available, were
carried out in the Dutch Surveillance Centre for Prion Diseases,
part of the University Medical Centre in Utrecht. Local ethical
committee approval was obtained for research on retained tissues
after written informed consent given by the patients during life or
their next of kin after death (Medical Ethics Committee of the
University Medical Centre Utrecht 11-531/C). All information
was analysed anonymously. The present study was restricted to
patients that had been evaluated during the calendar years 1998–
2009, as detailed clinical or neuropathological and biochemical
data were not available for cases that had been referred before that
time. When available, PRNP codon 129 genotypes from probable
cases (i.e. the patients who had not given permission for autopsy)
were analysed as well.
Case subjects underwent detailed evaluation using all available
medical and risk-related information, obtained from both medical
records, attending medical care providers and family interviews.
The clinical features were reviewed prospectively with special
attention given to initial symptoms, age at onset, disease duration
and typical CJD symptoms (dementia, ataxia, pyramidal and
extrapyramidal signs, myoclonus and akinetic mutism). Disease
onset was calculated starting from the presentation of neurological
signs or symptoms suggestive of organic involvement. Prodromal
symptoms, such as tiredness, depression, sleep disturbance,
abnormal appetite, weight loss and headache were not considered.
Disease duration was counted as time from disease onset to death.
A family history for neurodegenerative disease or a history of
potential iatrogenic exposure (e.g. from dura mater implants,
corneal grafts, or human cadaveric pituitary hormones) was
assessed in all cases.
Neuropathology
Brains were removed at autopsy and selected samples of tissue
from the temporal cortex, occipital cortex and cerebellum were
immediately frozen and stored at 280uC. The rest of the brain
was fixed in formalin and used for histological and immunohis-
tochemical purposes. Histopathological examination was per-
formed on 5-mm-thick sections of formalin-fixed and paraffin-
embedded brain tissue blocks, after decontamination for 1 hour in
concentrated formic acid (98%). Sections were taken from the
following areas: frontal (superior and middle frontal gyri), parietal
(superior and middle parietal gyri), temporal (middle temporal
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gyrus) and occipital (calcarine cortex) cortices, hippocampus
(Ammon’s horn) with trans(entorhinal) cortex, striatum (caudate
nucleus, putamen and globus pallidus), thalamus (anterior and
pulvinar), brainstem (midbrain including periaqueductal gray,
pons including locus coeruleus and medulla oblongata including
inferior olive nucleus) and cerebellum (vermis and hemisphere).
Haematoxylin-eosin and combined Luxol fast blue-periodic acid-
Schiff (PAS) stains were performed according to standard
procedures. The monoclonal antibody 3F4 (1:400, overnight at
4uC, Signet Labs, MA, USA) was used for PrP immunohisto-
chemistry. Pretreatment protocols for PrP staining involved
antigen retrieval by autoclaving in citric acid buffer pH 6.0 at
121uC for 10 minutes followed by incubation with Proteinase K
(10 mg/mL, for 5 minutes at room temperature). Evaluation of
spongiform change and immunohistochemical PrP deposits was
carried out in all cases of neuropathologically confirmed prion
disease by comparing Luxol fast blue-PAS sections from 17 brain
regions.
Genetic analysis
Genomic DNA from 161 subjects with neuropathologically
confirmed prion disease was extracted from blood or frozen brain
tissues and used to amplify the coding region of PRNP in the
polymerase chain reaction (PCR), as previously described [31].
The PCR products were visualized on 1% agarose gels to detect
potential insertions or deletions. Potential point mutations were
revealed by denaturing high pressure liquid chromatography
(dHPLC) analyses. In 60 patients (37.2%), mutations were also
ruled out by direct sequencing of the PRNP open reading frame
(ORF). The codon 129 genotype was examined by digestion with
the restriction endonuclease Nsp 1. All genetic analyses were
performed at the Dipartimento di Scienze Neurologiche, Uni-
versita` di Bologna, Italy, except for six cases with a positive family
history that had already been analysed by the Genome analysis
department of the Academic Medical Centre in Amsterdam, the
Netherlands. Information about the distribution of the codon
129 M/V polymorphism in the normal Dutch population was
obtained from a previous study [32] and provided by the National
Prion Disease Registry in Rotterdam, the Netherlands. The same
institution also provided data on the codon 129 polymorphism in
32 probable CJD patients of whom blood was available for genetic
analysis.
Prion protein analysis
Preparation of samples, Western blotting and PrPSc typing were
performed according to established methods [24,26,33,34]. Two
or three brain regions were examined, including the temporal
cortex, occipital cortex and/or cerebellum. All samples were
homogenized in lysis buffer plus [100 mmol/l NaCl, 10 mmol/l
EDTA, 0.5% (v/v) Nonidet P40, 0.5% (w/v) sodium deoxycho-
late, 100 mmol/l Tris-HCL) at pH 6.9, digested with proteinase K
(PK) (Roche Diagnostics, specific activity by certificate of analysis:
47.9 U/mg) at a final concentration of 10 U/ml and run in a
6.5 cm long separating gel. All immunoblots were probed with the
monoclonal antibody 3F4 with epitope at PrP residues 108–111 at
a 0.1 mg/ml concentration (Signet Labs, MA, USA). If immuno-
histochemistry had shown a mixed pattern of PrPSc deposition,
whereas no evidence for or only scanty and focal type 2
accumulation had been found during immunoblotting, blots were
also probed with the monoclonal antibody 1E4 with epitope at PrP
residues 98–100 at 2 mg/ml concentration (Sanquin Reagents,
Amsterdam, the Netherlands) as described [24]. All immunoblots
were performed at the Dipartimento di Scienze Neurologiche,
Universita` di Bologna, Italy.
sCJD subtype classification
sCJD cases were classified according to Parchi et al. [24] based
on the combined results of neuropathological examination, prion
protein isotyping, and codon 129 genotyping. This updated
classification system includes six ‘‘pure’’ subtypes of sCJD that are
largely defined by the PrPSc type/codon 129 genotype combina-
tion and identified as (1) MM1/MV1; (ii) VV2; (iii) MV 2K; (iv)
MM 2C; (v) MM 2T; and (vi) VV1 [14], and at least 4 additional
‘‘mixed’’ subtypes (MM/MV 1+2C, MM/MV 2C+1, VV 2+1,
MM/MV 2 K+C) showing the co-occurrence of phenotypic
features of two ‘‘pure’’ subtypes in the same brain. In the present
study, the finding of mixed features at histopathological examina-
tion or the co-occurrence of PrPSc types 1 and 2 on western
blotting was considered sufficient to attribute a case to a ‘‘mixed’’
subtype. In brief, the pathological phenotype of the MM/MV
1+2C largely overlaps with that of pure MM/MV 1 cases but also
shows a) large vacuoles, often forming grape-like confluent foci of
spongiform changes in addition to the classic microvacuolation of
the MM1/MV1 subtype and b) a mixed synaptic/perivacuolar or
coarse pattern of PrP staining. The pathological phenotype of
MM/MV 2C+1 largely corresponds to that of the MM/MV 2C
subtype, with the exception of a synaptic pattern of PrP staining in
the cerebellum. The MV 2 K+C subtype is characterized by type
‘‘2C’’ pathology (as described above for MM/MV 1+2C)
superimposed on the classic MV 2K lesion profile. And finally,
the VV2+1 subtype can only be diagnosed by PrPSc typing, since
the pathological phenotype in these subjects is very similar to that
of VV2 cases.
Statistical analysis
Means, tests of normality, x2-tests and Kruskal-Wallis tests were
performed using the Statistical Package for the Social Sciences
package version 16.0 (SPSS Inc.). Statistical significance was
defined as P,0.05. Incidence was calculated as the number of
newly detected definite (e.g. pathologically confirmed) and probable
TSE cases per year per million inhabitants. Since prion diseases
are invariably fatal and illness duration is usually less than one
year, the incidence and mortality were considered equal.
Denominator population data for the years 1998–2009 were
provided by the Department of Epidemiology of the Erasmus
University in Rotterdam, The Netherlands.
Results
All patients with clinical suspicion of prion disease
Between January 1998 and December 2009, 451 patients with a
clinical suspicion of prion disease were registered by the Dutch
National Prion Disease Registry in Rotterdam. Of these, 295
patients were notified prospectively and 156 patients were
reported after death. Most of the latter were referred directly for
post mortem examination to the Dutch Surveillance Centre for
Prion Diseases in Utrecht without central registration in
Rotterdam. Overall, 318 of the 451 registered patients with
suspected prion disease underwent post-mortem examination,
equalling an autopsy rate of 70.5%. The relationship between
clinical classification and post-mortem results in this group is
provided in Table 1. Total autopsies averaged 27 per year
(Table 2). A definite diagnosis of prion disease was confirmed in
162 patients (50.9%) and in 156 patients (49.1%) neuropathology
failed to detect prion disease. Overall, of all patients with
neuropathologically confirmed prion disease (n=162), 134 pa-
tients (82,7%) were notified prospectively. The remaining 28
patients (17,3%) were reported after death. There were 52 patients
classified as probable CJD among the 133 referred cases in which no
Human Prion Diseases in The Netherlands
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Table 1. Patients sorted by clinical classification with autopsy results.
Autopsy results
Clinical classification Total (n) Definite CJD (n) Non-CJD (n)
Clinical classification as 161 (50.6%) 127 (78.4%) 34 (21.8%)
‘‘probable CJD’’
sCJD (n = 119) Alzheimer/CAA (n = 6)
gCJD (n = 2) Multi-infarction (n = 5)
iCJD (n = 4) Alzheimer/Alzheimer changes (n = 4)
vCJD (n = 2) Auto-immune encephalopathy (n = 6)
Lewy Body Dementia (n = 3)
Non-Hodgkin Lymphoma (n = 2)
Alzheimer/infarction (n = 2)
Frontotemporal Dementia (n = 1)
Metastasis (n = 1)
Pinealoblastoma (n = 1)
Unknown aetiology/other (n = 3)
Clinical classification as 49 (15.4%) 19 (11.7%) 30 (19.2%)
‘‘possible CJD’’
sCJD (n = 16) Alzheimer/Alzheimer changes (n = 7)
gCJD (n = 1) Lewy Body Dementia (n = 6)
VPSPr (n = 1) Auto-immune encephalopathy (n = 4)
iCJD (n = 0) Frontotemporal Dementia (n = 2)
vCJD (n = 1) Progressive Multifocal Leuko-encephalopathy
(n = 2)
Alzheimer/CAA (n = 2)
Non-Hodgkin Lymphoma (n = 1)
Metastasis (n = 1)
Alzheimer/infarction (n = 1)
Multi-infarction (n = 1)
Viral encephalitis (n = 1)
Unknown aetiology/other (n = 2)
Clinical classification as 108 (33.9%) 16 (9.9%) 92 (59.0%)
‘‘other disease’’
sCJD (n = 9) Alzheimer/Alzheimer changes (n = 21)
gCJD (n = 6) Multi-infarction (n = 13)
iCJD (n = 1) Alzheimer/infarction (n = 9)
vCJD (n = 0) Lewy Body Dementia (n = 7)
Auto-immune encephalopathy (n = 6)
Infectious (n = 5)
Alzheimer/CAA (n = 4)
Frontotemporal Dementia (n = 3)
Non-Hodgkin Lymphoma (n = 3)
Metastasis (n = 2)
Multiple sclerosis (n = 2)
Spinocerebellar ataxia (n = 1)
Amyotrophic lateral sclerosis (n = 1)
Toxic metabolic (n = 1)
Unknown aetiology/other (n = 14)
318 (100%) 162 (100%) 156 (100%)
CJD=Creutzfeldt-Jakob disease; sCJD = sporadic Creutzfeldt-Jakob disease; gCJD= genetic Creutzfeldt-Jakob disease; iCJD= iatrogenic Creutzfeldt-Jakob disease;
vCJD = variant Creutzfeldt-Jakob disease; VPSPr = variably protease-sensitive prionopathy; CAA= cerebral amyloid angiopathy.
doi:10.1371/journal.pone.0036333.t001
Human Prion Diseases in The Netherlands
PLoS ONE | www.plosone.org 4 April 2012 | Volume 7 | Issue 4 | e36333
permission for autopsy was obtained. Blood and/or frozen tissues
were available for further biochemical and genetic studies in 161
patients with definite prion disease. There were 9 patients (5.6%) in
whom PRNP genotyping confirmed a genetic form of TSE. The
total annual mortality of TSE in the Netherlands has remained
more or less stable (P=0.06, x2-test) over the observation period,
ranging from 0.63 to 1.53 per million inhabitants per annum
(Table 2).
Patients with sCJD
A definite diagnosis of sCJD was made in 144 patients (88.9% of
all patients with definite prion disease). The mean age at onset was
67 years (range 35 to 85 years) and the mean disease duration 6.5
months (range 1 to 36 months). In this group, 62 patients (43.0%)
were males and 82 patients (57.0%) females. Genetic analysis for
the codon 129 MV polymorphism in all definite sCJD cases
(available in n=143) revealed 101 (70.6%) MM cases, 32 (22.4%)
MV cases and 10 (7.0%) VV cases (Table 3). The sCJD codon
129 distribution in The Netherlands is comparable to the sCJD
distribution in the surrounding Western European countries
[14,35] (P=0.05, x2-test), although there was a trend for under-
representation of VV cases (P=0.06).
Frozen tissue was available for immunoblotting in 140 of 144
patients with neuropathologically confirmed sCJD. Molecular
typing by western blotting showed that 71 cases had only PrPSc
type 1, 33 only PrPSc type 2 and 36 cases the presence of both
PrPSc types 1 and 2 (Table 4). Similar to previous studies [24], the
PrPSc type 1 and 2 protein mixture was detected in each subtype,
but more frequently in MM than in MV or VV cases. Finally, 3
cases showed a distinctive atypical profile characterized by
truncated protein fragments of relatively low molecular weight
on immunoblotting or histopathological features that were not
consistent with any of the specified molecular subgroups.
Cases were classified according to Parchi et al. [24] based on
molecular features and neuropathological lesion profiles, and their
subgroup allocation is shown in Table 5. A pure phenotypic
subtype was found in 60.1% of the sCJD patients, whereas mixed
phenotypes (determined by either PrPSc or histopathological
Table 2. Mortality and classification of all definite and probable TSE patients.
Year of
surveillance 1998 1999 2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 total
Notified
prospectively
40 46 41 32 36 32 37 37 46 37 38 29 451
Referred for post-
mortem examination
25 28 20 18 26 19 26 32 38 30 33 23 318
Total number of
patients with TSE*
18 20 10 17 18 13 22 23 25 17 18 13 214
Aetiology of definite
TSE
Sporadic CJD 12 16 6 8 11 7 13 17 19 10 15 10 144
Iatrogenic CJD 1 1 0 1 0 1 1 0 0 0 0 0 5
Inherited CJD 0 0 0 0 0 0 0 0 1 2 0 0 3
GSS 0 0 0 1 0 0 1 1 1 0 0 0 4
PrP-CAA 0 0 0 0 0 0 0 0 0 0 1 0 1
FFI 0 0 0 0 0 0 0 0 0 0 1 0 1
Variant CJD 0 0 0 0 0 0 0 1 1 0 0 1 3
VPSPr 0 0 0 0 0 0 0 1 0 0 0 0 1
Subtotal 13 17 6 10 11 8 15 20 22 12 17 11 162
Mortality TSE** 1.20 1.30 0.63 1.07 1.13 0.81 1.34 1.41 1.53 1.04 1.10 0.78
Mortality sCJD** 1.13 1.24 0.63 0.88 1.13 0.75 1.22 1.22 1.34 0.92 0.98 0.66
TSE = Transmissible Spongiform Encephalopathy; CJD=Creutzfeldt-Jakob disease; sCJD= sporadic Creutzfeldt-Jakob disease; GSS =Gerstmann-Stra¨ussler-Scheinker
disease; PrP-CAA=prion protein cerebral amyloid angiopathy; FFI = Fatal Familial Insomnia; VPSPr = variably protease-sensitive prionopathy.
*Definite and probable cases.
**Per million inhabitants per annum.
doi:10.1371/journal.pone.0036333.t002
Table 3. Codon 129 distribution in the normal Caucasian and Dutch population and in sCJD patients [32,35,46].
Codon 129
Normal Western European
population (%)
Normal Dutch population
(%)
Sporadic CJD in Western
Europe (%)
Sporadic CJD in The
Netherlands (%)
MM 44.1 45.1 71.0 70.6
MV 44.5 45.6 13.0 22.4
VV 11.4 9.3 16.0 7.0
M=methionine; V = valine.
doi:10.1371/journal.pone.0036333.t003
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typing or both) were observed in 39.9% of patients. The subtype
allocation was based on results of both neuropathological
examination and prion protein isotyping in 127 patients (i.e. the
results of both examinations were compatible). In 13 patients,
neuropathological examination identified the distinctive features of
the MM/MV 2C subtype despite the absence of a type 2 band on
immunoblotting, while the two VV 2+1 cases were recognized by
PrPSc immunoblotting. Similar to earlier results, the various
subgroups showed differences in disease duration (P,0.01,
Kruskal-Wallis test). Mean disease duration stratified by molecular
subgroup was the shortest for MM/MV 1 with 3.0 months (range
1–8) and longest for the MV 2 K+C and MM/MV 2C+1
subgroups with 15.6 months (range 4–36 months, excluding single
cases in the MM 2C and MM 2T subgroups) (Table 5).
In total, 70.6% of patients with sCJD died within 6 months of
illness onset, and 53.8% died within 3 months. A disease duration
of more than 24 months was found in 5 sCJD patients (3,5%).
Interestingly, four of them belonged to the MV 2K or MV 2 K+C
subgroups. Although previous reports have suggested that long
disease duration, especially in Japanese sCJD patients, may reflect
differences in the clinical management, this is likely not the case in
our cohort of patients, as ventilation and life-sustaining treatment
are only seldom used in patients with CJD in Europe. Altogether,
four sCJD patients (two MM1, one MV1 and one MM 2T) with
age at onset below 50 years were examined, the youngest patient
at the age of 35 years. The age group over 80 years at onset
consisted of 8 patients (5.6%), all within the MM1 and MM 1+2C
subgroups.
Patients with genetic prion disease
Within the group of patients with definite prion disease available
for mutation analysis, 9 patients (5.6%) were positive for a PRNP
mutation. All patients with the same mutation belonged to the
same family. These patients had been analysed on the basis of
positive family history or unusual clinical and neuropathological
features. Genetic analysis for PRNP revealed 4 patients with GSS,
3 patients with gCJD, 1 patient with PrP cerebral amyloid
angiopathy and 1 patient with FFI (Table 6). Several patients
were already published as case reports [36–40]. Genetic analysis of
the remaining 152 patients with definite prion disease revealed eight
A117A, 129V polymorphisms (4.9%), two DelR3/R4, 129M
polymorphisms (1.2%) and one G124G, 129M polymorphism
(0.6%), but no pathogenic mutations. This was confirmed by direct
sequencing of the PRNP ORF in 51 (33.5%) cases.
Patients with iCJD
During the 11 years of surveillance, we identified 5 patients with
iatrogenic CJD (4 patients due to dura mater grafts and 1 patient
after hGH injections) (Table 7). The disease duration ranged
from 2 to 9 months. The dura mater patches were performed
between 1982 and 1988. In all patients LyoduraH was used,
produced by Melsungen AG in Germany. Incubation time varied
from 10 to 21 years (mean 16.0 years). Two of these patients
showed a VV1 molecular subtype, whereas the other two patients
showed a MM1 and MV1 subtype, respectively. The hGH
injections were given in 1963 as part of a diagnostic process. The
Table 4. PRNP genotype and PrP type in 140 sCJD patients.
Type MM MV VV Total
Type 1 63* (64.3) 8 (25.0) 0 (0) 71 (50.7)
Type 1+2 concurrence 32 (32.6) 2 (6.3) 2 (20.0) 36 (25.7)
Type 2 3 (3.1) 22 (68.7) 8 (80.0) 33 (23.6)
Total 98 32 10 140
MV 1+2 are 2 cases without Kuru plaques, MM2 includes 1 MM 2C and 2 MM 2T
cases, whereas MV2 includes 14 MV 2K cases and 8 MV 2 K+C cases.
% are expressed in brackets and refer to each single column.
N in 13 cases the histopathological findings suggested the additional presence
of type 2.
doi:10.1371/journal.pone.0036333.t004
Table 5. Classification of sporadic CJD subtypes in the Dutch population based on combined molecular and histopathological
assessment.
No. cases % Mean age at onset (years) Mean duration (months)
Pure subtypes 83 58
MM1/MV1 58 40.6 67 (42–85) 3 (1–8)
VV2 8 5.6 72 (61–80) 7.9 (3–24)
MV 2K 14 9.1 63 (53–74) 13.5 (3–36)
MM/MV 2C 1 ,1 69 16
MM 2T 2 1.4 47 (35–58) 26 (18–34)
Mixed subtypes 57 39.9
MM/MV 1+‘‘2C’’ 42* 29.4 68 (50–82) 4.0 (1–15)
MM/MV 2C+1 5 3.5 66 (54–73) 15.6 (12–21)
VV 2+1 2 1.4 59 6
MV 2 K+C 8 5.6 68 (57–75) 15.6 (4–36)
Atypical 3 2.1 67 (63–74) 12.7 (10–16)
Nomenclature is largely based on the codon 129 genotype, which can be either methionine (M) or valine (V) and the PrPSc type (type 1 or 2, according to Parchi et al.)
Since both MM2 and MV2 groups are associated to 2 distinct phenotypes, these are further defined with a third parameter (capital letter) referring to distinctive
histopathological features: K kuru type amyloid plaques, C predominant cortical pathology with confluent vacuoles and perivacuolar PrP staining, T prominent thalamic
pathology with atrophy.
*In 13 patients, neuropathological examination identified the distinctive feature of the MM/MV 2C subtype (i.e. grape-like clusters of spongiform change with a coarse
PrP immunohistochemical staining pattern), but the type 2 band on immunoblotting was not detected.
doi:10.1371/journal.pone.0036333.t005
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original supplier could not be retrieved anymore from the hospital
records. This patient developed CJD at the age of 47 years, after
an incubation period of 38 years, the longest ever reported [41].
The disease duration was 6 months and on immunoblotting he
showed a MM1 subtype.
Patients with vCJD
Between 1998 and 2009, three patients with vCJD were
diagnosed. The first patient was identified in 2005 [42], the other
two were reported in 2006 and 2008. Patient characteristics are
provided in Table 8.
Patient with VPSPr
Recently, Gambetti et al. identified a novel form of variably
protease-sensitive prionopathy (VPSPr), characterized by the
presence of an abnormal PrP species that was largely sensitive to
PK digestion [29,43]. After re-evaluating cases with atypical
dementias in the Dutch surveillance program, we were able to
identify one case of VPSPr in a patient was homozygous for valine
at codon 129 of PRNP. This patient was reported as a case study
[44].
Patients with other disease
In 156 patients, neuropathology failed to detect any evidence of
prion disease. In 36.0% of these cases, another neurodegenerative
disease was neuropathologically confirmed, such as Alzheimer’s
disease (21.2%), Lewy body dementia (9.6%) and frontotemporal
lobar degeneration (3.8%) (Table 9). A substantial group
(,14.0%) suffered from a potentially treatable disorder such as
infectious disease, tumour-associated disease or toxic/metabolic
disorders. Vascular disease (,20%) and autoimmune encepha-
lopathy (10,3%) were responsible for most remaining cases.
Thirteen patients (8.3%) had co-existent pathology in the form
of a vascular event superimposed on Alzheimer’s disease,
explaining the rapid deterioration in the later stages of the disease
course.
Discussion
This study analyses the results of National Surveillance for TSEs
over a 12 year period within the population of 16 million
inhabitants of the Netherlands since 1998. To our knowledge, this
is the first time that epidemiological, genetic and molecular data,
including information about the incidence of pure and mixed
sCJD subtypes have been provided comprehensively for a single
country. Most countries that have undertaken surveillance over an
extended period of time have reported a steadily progressive
increase in the recorded incidence of sCJD [3,45]. This has been
attributed to enhanced case detection and reporting. In this study,
however, we found a more or less stable incidence and mortality
from TSE and sCJD during the years 1998–2009, ranging from
0.63 to 1.53 per million inhabitants per annum.
The clinical and pathological phenotypes of our sCJD patients
were fully compatible with the updated classification scheme
proposed by Parchi et al. [14,24], except for 3 atypical cases which
defied classification. Codon 129 polymorphism analyses revealed a
more or less similar genotype distribution compared to previously
reported distribution in other cohorts [14,35], with an increase of
MM homozygotes (70.6%) compared to the normal population.
Interestingly, although not statistically significant, the proportion
of MV heterozygous sCJD patients tended to be higher than that
reported in other studies [14,35,45,46], whereas the VV
homozygous patients were relatively underrepresented. Although
the relatively high proportion of 129VV patients in our probable
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CJD group (i.e. 25% of a group of 32 tested cases), may, at least in
part, compensate for the observed abnormal distribution in the
definite CJD group, the finding is overall intriguing and deserves
consideration and future follow-up. The codon 129 distribution in
the normal Dutch population is comparable to other Western
European countries [46–48].
An important aspect of sCJD phenotypic variability concerns the
existence of cases presenting more than one PrPSc type and/or
mixed histopathological features in the same brain. In previous
studies, the proportion of cases with concurrent PrPSc types varied
between 12 and 44% and was believed to be a function of the
sampling protocol that was employed [14,17–22]. Recently,
however, Parchi et al. carried out a systematic study in a large
series of Italian, German and North-American sCJD patients and
found the co-occurrence of characteristic features (either molecular
or histopathological or both) of two distinct sCJD subtypes in about
40% of cases [24]. For a reliable sCJD group classification, the
authors recommended a protocol including the neuropathological
assessment of at least eight brain regions and PrPSc typing in four
critical regions, such as the temporal, parietal and occipital
neocortices, and medial thalamus. By applying this protocol with
some modifications (e.g. only two of the four recommended brain
regions were available for typing), we performed group classification
for the Dutch sCJD patients. The results were largely compatible
with the updated classification by Parchi et al. [24]. A mixed sCJD
subtype, inferred from either neuropathological examination, the
results of immunoblotting or both analyses, was again found in
about 40% of patients and was higher in MM than in MV or VV
subjects. In the present study, neuropathological examination was
more sensitive than PrPSc typing in identifying the distinctive
features of the MM/MV 2C subtype when associated focally to the
MM/MV1 subtype, the result being at least partially explained by
the relative low number of brain areas available for PrPSc typing.
Our observations reinforce the usefulness of the proposed protocol
for typing of sporadic CJD cohorts and underline the necessity of
careful histopathological evaluation, particularly when the avail-
ability of frozen tissue for PrPSc typing is limited.
In contrast with this and other studies [23,24,26,49], others [25,50]
have suggested that it may not be possible to place firm restrictions on
the prevalence of cases with mixed PrPSc types. By using type-1 [25]
and type-2 [50] selective antibodies, these studies detected, in little
amounts, type-1 PrPSc in all patients with sCJD type 2 and type-2
PrPSc in all patients with sCJD MM1. Although the interpretation
and relevance of these data for CJD classification and strain-typing
was contested [26,49], by showing that such PrPSc-selective
antibodies recognize PrP fragments that do not match the
physicochemical properties of those detected with standard PrPSc
typing, an issue that was also discussed in the latter of these studies
[50], these results are of interest and further investigations are
required to unravel the biological basis of co-occurrence of PrP types.
In the Netherlands, only 5 iatrogenic CJD cases were identified
over a 12 year period, corresponding to a lower incidence (3,1%)
than for other countries with CJD surveillance [51]. Similarly,
genetic analysis of PRNP in 162 patients with neuropathologically
confirmed prion disease revealed a mutation in only nine of them,
corresponding to an incidence of 5,6%. This figure is slightly lower
then the average rate of inherited prion diseases in Europe (9,5%)
[45], but higher than the previously reported 2% for the
Netherlands [30] and comparable to the figures from neighbour-
ing Germany [45]. The slightly lower rate of inherited prion
disease in the Dutch population cannot be a result of under-
detection of PRNP mutations, since all cases with definite prion
disease were genotyped in this study. Interestingly, some of the
most frequent mutations (e.g. P102L, E200K and V210I) in
Caucasian populations, including those from the surrounding
Western European countries [30,45], were not identified in the
Netherlands, possibly related to the relatively small study group.
Other than the codon 129 MV polymorphism, the two most
common non-pathogenic PRNP variants in the Dutch population
were A117A (4.9%) and a 24 bp deletion in the octapeptide repeat
region (1.2%). These data are comparable to other studies [46].
Many reports on patients with clinical syndromes mimicking CJD
are found in the literature with a broad range of diagnoses. Analysis
of differential diagnosis revealed Alzheimer’s disease as the most
Table 7. Demographic characteristics of all patients with iatrogenic CJD (1998–2009).
Year of death
Age at onset
(years)
Disease duration
(months)
Incubation period
(years) PrPSc type Codon 129 (M/V)Mode
1998 51 6 14 1 VV Dura mater graft
1999 54 4 10 1 MM Dura mater graft
2001 47 6 38 1 MM HGH injections
2003 66 9 21 1 MV Dura mater graft
2004 65 2 19 1 VV Dura mater graft
hGH=human Growth hormone; M=methionine; V = valine.
doi:10.1371/journal.pone.0036333.t007
Table 8. Demographic characteristics of all patients with new variant CJD.
Year of diagnosis Age at onset (years) Disease duration (months) Codon 129 (M/V) Symptoms at disease onset
2005 24 20 MM anxiety, forgetfulness
2006 14 15 MM concentration disturbance
2009 48 14 MM depression, anxiety
M=methionine; V = valine.
doi:10.1371/journal.pone.0036333.t008
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frequent other diagnosis among our patients (21.2%). This is not
surprising, as it represents the most frequent cause of dementia in
the elderly. Other diagnoses such as immunologically mediated
dementia, multi-infarction dementia and neoplastic disease also
presented with a clinical syndrome similar to that of prion disease.
Many of these patients were referred to the National Prion Disease
Registry on the basis of a false-positive 14-3-3 test in cerebrospinal
fluid, myoclonus, akinetic mutism or an accelerated decline in the
later stages of disease, most often caused by superimposed vascular
disease (e.g. infarction). The high number of non-TSE cases in our
study (,50%) at least seems to indicate that the surveillance system
in the Netherlands is very accessible to all treating physicians.
In conclusion, the incidence and mortality rates of sCJD in the
Netherlands are similar to those in other European countries,
whereas iatrogenic and genetic cases are relatively rare. The
unusual incidence of the VV2 sCJD subtypes compared to that
reported in other Western countries deserves further investigation.
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